John Carroll’s Post

It was a pleasure hosting my friend and colleague, Professor Leslie Benet of UCSF, school of Pharmacy at Emery Pharma. The title of his talk: The explanation for WHY and when bioavailability calculation exceed unity? A brief introduction on Les: Professor Les Benet of UCSF School of Pharmacy is a leading authority on pharmacokinetics, investigating how drugs behave in the body. His expertise lies in understanding how medications are absorbed, distributed, metabolized, and excreted. His work has significantly impacted pharmaceutical research, guiding the effectiveness and safety of various drugs. https://lnkd.in/gQ3AXS3Q

The Final Agendas for https://lnkd.in/ev2K3bR are posted! The event is in San Diego April 1-4, 2024. Plenary Keynotes are Daniel Nomura of UC Berkeley and Double Nobel Laureate, Barry Sharpless of Scripps. There will be 5 parallel day-and-a-half conference tracks in each half and 3 parallel symposia the day before the main event. You can attend anything that runs concurrently with the track for which you register (and access most of what you missed On Demand). #drugdiscoverychemistry, #medicinalchemistry

Check out my blog post on smart cities here: https://wix.to/7Z0sY0V I will also present shortly the relative paper in @Geoinno24 #smartcities #complexity #innovation #patents #economics

Did you know you can explore the realm of drug discovery and development with our Science Pool? Dive into the latest breakthroughs and insightful perspectives on our dedicated content site. Immerse yourself in the wealth of knowledge found in our Blog Section! From innovative approaches to therapeutic advancements, our blogs cover it all. Check out the enlightening articles at - https://hubs.ly/Q029q5m_0 Why Science Pool? - Curated content from leading experts in drug discovery - Stay updated on the forefront of pharmaceutical advancements - Engaging articles for all knowledge levels Join our community of pharmaceutical enthusiasts! Uncover the intricacies of drug development one blog post at a time. #researchneverstops

According to the United Nations, the proportion of people aged over 65 now outnumber children younger than 5. The enormous #growth in the #elderly population is posing a #socioeconomic #challenge to societies worldwide, and necessitates new sweeping interventions for age-associated diseases. This year we have an incredibly exciting program with global thought-leaders sharing their latest insights into aging and how we target aging process ensuring everyone lives a healthier and longer life.

David Stuarts draws the life sciences environment in Life Science Leader to present the M&A outlook for 2024. He summarizes the life sciences as the most dynamic sector of the economy, highlighting its challenges and opportunities. Challenges: -Increased antitrust scrutiny -Inflation uncertainty and cost of capital -Geopolitical tensions. Opportunities: -The rise of new technologies -Growing demand for personalized medicine -Emerging markets expansion. https://lnkd.in/e7e6vSmz

At the Delhi Chapter of the Great Science Seminar on September 15, join us for a compelling keynote talk by renowned industry expert, Dr. Arvind Kumar Sharma, as he shares invaluable insights on – Evolution of Indian Pharmacopoeia Commission in strengthening the Quality of Indian Pharmaceutical Industry. Hurry, limited seats available. Register today - https://bit.ly/3qKWG24 #pharmaceuticals #labproductivity #regulatorycompliance #analyticalinstruments #AgilentIndia

What's to come in 2024 - check out this summary of the latest trends and developments for life science companies.

The article reached 3,000 reads Achieved on March 25, 2024 Title: Stimuli-Responsive Polymers for Transdermal, Transmucosal and Ocular Drug Delivery since it was published December 2021 Pharmaceutics 13(12):2050 DOI: 10.3390/pharmaceutics13122050 Despite their conventional and widespread use, oral and intravenous routes of drug administration face several limitations. In particular, orally administered drugs undergo enzymatic degradation in the gastrointestinal tract and first-pass metabolism in the liver, which tend to decrease their bioavailability. Intravenous infusions of medications are invasive, painful and stressful for patients and carry the risk of infections, tissue damage and other adverse reactions. In order to account for these disadvantages, alternative routes of drug delivery, such as transdermal, nasal, oromucosal, ocular and others, have been considered. Moreover, drug formulations have been modified in order to improve their storage stability, solubility, absorption and safety. Recently, stimuli-responsive polymers have been shown to achieve controlled release and enhance the bioavailability of multiple drugs. In this review, we discuss the most up-to-date use of stimuli-responsive materials in order to optimize the delivery of medications that are unstable to pH or undergo primary metabolism via transdermal, nasal, oromucosal and ocular routes. Release kinetics, diffusion parameters and permeation rate of the drug via the mucosa or skin are discussed as well.

https://lnkd.in/eqiyAHbw Highly encourage anyone involved with or interested in the drug development industry to listen to this short interview of Howison Schroeder, CEO of Neuro-Innovators, LLC about his company and investigative pharmaceutical drug cocktail to deal with neurological issues post stroke.    Neuro-Innovators groundbreaking, non-psychedelic, neuroplastic drug development program gives NIV-Neuro a substantial strategic, early mover advantage. They are one of three companies known to be pursuing a therapeutic solution for stroke recovery and the only company with an accelerated repurposing strategy. Their strategy positions NIV-Neuro exceptionally well to be first with a drug to help chronic patients (6+ months past event!) recover function - a $20+ billion unmet need.